Logo     Print Page  Close Window


SEC Filings


10-Q
FIBROCELL SCIENCE, INC. filed this Form 10-Q on 08/09/2018
Entire Document
 

Fibrocell Science, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
($ in thousands) 
 
Six months ended June 30,
 
2018
 
2017
Cash flows from operating activities:
 

 
 

Net loss
$
(5,795
)
 
$
(19,025
)
Adjustments to reconcile net loss to net cash used in operating activities:
 

 
 

Stock-based compensation expense
260

 
63

Warrant revaluation expense (income)
(326
)
 
9,723

Derivative revaluation income
(179
)
 
(541
)
Depreciation and amortization of long lived assets
202

 
184

Loss on disposal or impairment of property and equipment

 
40

Decrease (increase) in operating assets:
 

 
 

Prepaid expenses and other current assets
30

 
72

Other assets

 
(19
)
Increase (decrease) in operating liabilities:
 
 
 
Accounts payable
51

 
192

Related party payable
(2,027
)
 
736

Accrued expenses and deferred rent
(74
)
 
(776
)
Accrued interest payable
382

 
368

Net cash used in operating activities
(7,476
)
 
(8,983
)
Cash flows from investing activities:
 

 
 

Purchase of property and equipment
(83
)
 
(243
)
Net cash used in investing activities
(83
)
 
(243
)
Cash flows from financing activities:
 

 
 

Proceeds from 2017 Series A Preferred Stock Offering, (net of offering costs of $377)

 
7,623

Payment of deferred offering costs
(444
)
 

Proceeds from conversion of pre-funded warrants
24

 

Proceeds from conversion of common warrants
499

 

Proceeds from May 2018 Registered Direct Offering, (net of offering costs of $527)
5,473

 

Net cash provided by financing activities
5,552

 
7,623

Effect of exchange rate changes on cash balances

 

Net increase (decrease) in cash and cash equivalents
(2,007
)
 
(1,603
)
Cash and cash equivalents, beginning of period
17,417

 
17,515

Cash and cash equivalents, end of period
$
15,410

 
$
15,912

Supplemental disclosures of cash flow information:
 
 
 
Non-cash investing and financing activities:
 
 
 
Property and equipment in accounts payable
$
52

 
$
26

Offering costs in accounts payable and accrued expenses
$
100

 
$

Reduction of warrant liability upon cashless exercise of warrants
$

 
$
41

Reduction in interest payable upon cashless exercise of promissory notes
$

 
$
2

Dividend paid in-kind to preferred stockholders
$
165

 
$
100

Deemed dividend on preferred stock
$
247

 
$
3,870

 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

8